Literature DB >> 2767025

Rhodococcus equi foal pneumonia: protective effects of immune plasma in experimentally infected foals.

R J Martens1, J G Martens, R A Fiske, S K Hietala.   

Abstract

The immunoprophylactic capacity of specific immune plasma was evaluated in pony foals infected experimentally with Rhodococcus equi. Immune plasma, produced by repeated parenteral administration of viable R. equi to adult horses, was harvested and frozen. Group I (six control foals) and Group II (six principal foals) received lactated Ringers solution and immune plasma respectively at three and five days of age. R. equi were aerosolised into a caudal lung lobe of all foals at seven days of age. Clinical signs, haematological alterations, immune responses, thoracic radiographs and technetium99m pulmonary perfusion scans were monitored. All foals were destroyed and complete post mortem examinations performed. All foals developed pneumonia as evidenced by clinical, radiographic and perfusion alterations, but the survival rate of principal foals was significantly (P less than 0.01) greater than that of control foals. Five control foals developed terminal disease, whereas all principal foals recovered. There was no significant (P greater than 0.05) difference in temperature response, or peripheral blood leucocyte, neutrophil or fibrinogen concentrations between groups. ELISA values for R. equi antibody were significantly (P less than 0.001) greater in principal foals following treatment, but there was no significant (P greater than 0.05) difference in IgG or IgM concentrations between groups. Results of the haemolysis inhibition assay indicated that equi factor neutralising antibodies were transferred by immune plasma to the principal foals. Post mortem examinations of five control foals destroyed at approximately three weeks post infection because of terminal disease, revealed severe pyogranulomatous pneumonia. One control and all principal foals were either free of lesions or had resolving lesions and/or minimal scar formation at three months post infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2767025     DOI: 10.1111/j.2042-3306.1989.tb02161.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  22 in total

1.  Identification of 15- to 17-kilodalton antigens associated with virulent Rhodococcus equi.

Authors:  S Takai; K Koike; S Ohbushi; C Izumi; S Tsubaki
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Identification of pulmonary T-lymphocyte and serum antibody isotype responses associated with protection against Rhodococcus equi.

Authors:  A Marianela Lopez; Melissa T Hines; Guy H Palmer; Debra C Alperin; Stephen A Hines
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

3.  Serologic responses to Rhodococcus equi in individuals with and without human immunodeficiency virus infection.

Authors:  V Vullo; C M Mastroianni; M Lichtner; F Mengoni; E Chiappini; C D'Agostino; S Delia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

4.  Clearance of virulent but not avirulent Rhodococcus equi from the lungs of adult horses is associated with intracytoplasmic gamma interferon production by CD4+ and CD8+ T lymphocytes.

Authors:  Stephen A Hines; Diana M Stone; Melissa T Hines; Debby C Alperin; Donald P Knowles; Linda K Norton; Mary J Hamilton; William C Davis; Travis C McGuire
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

5.  PNAG-specific equine IgG1 mediates significantly greater opsonization and killing of Prescottella equi (formerly Rhodococcus equi) than does IgG4/7.

Authors:  Joana N Rocha; Lawrence J Dangott; Waithaka Mwangi; Robert C Alaniz; Angela I Bordin; Colette Cywes-Bentley; Sara D Lawhon; Suresh D Pillai; Jocelyne M Bray; Gerald B Pier; Noah D Cohen
Journal:  Vaccine       Date:  2019-01-26       Impact factor: 3.641

Review 6.  Rhodococcus equi: an animal and human pathogen.

Authors:  J F Prescott
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  Molecular characterization of a lipid-modified virulence-associated protein of Rhodococcus equi and its potential in protective immunity.

Authors:  C Tan; J F Prescott; M C Patterson; V M Nicholson
Journal:  Can J Vet Res       Date:  1995-01       Impact factor: 1.310

8.  Role of T-lymphocyte subsets in Rhodococcus equi infection.

Authors:  P Nordmann; E Ronco; C Nauciel
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

Review 9.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

10.  Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provide protection against Rhodococcus equi infection.

Authors:  Aline F Oliveira; Luciana P Ruas; Silvia A Cardoso; Sandro G Soares; Maria-Cristina Roque-Barreira
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.